A Phase III Randomized, Open-Label Study Evaluating Efficacy and Safety of Giredestrant Compared With Fulvestrant, Both Combined With a CDK4/6 Inhibitor, in Patients With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer With Resistance to Prior Adjuvant Endocrine Therapy
- Sponsor:
- Roche Pharmaceuticals
- Sponsor Study ID:
- CO44657
- CTO #:
- 104139
- NCT Number:
- NCT06065748
- Phase:
- III
- Protocol Type:
- Treatment
- Age Group:
- Adults
- Disease Sites:
- Breast
- Study Objectives:
- To evaluate the efficacy of Giredestrant compared with fulvestrant (both combined with CDK4/6i) in the ESR1m subgroup and FAS.
- eConsent:
- Not available
- Study Documents:
-
Open Study Documents
(MUSC NetID required for document access)
For more information about this trial please contact the study team:
-
Medical University of South Carolina
- Principal Investigator, Sivapiragasam, Abirami, at sivapira@musc.edu .
- Study Coordinator, Bargeloh, Zachary, at bargeloh@musc.edu .
Trial opened at the following institutions:
Medical University of South Carolina